OBJECTIVES: Although information is available on how adults with epilepsy value their quality-of-life (QoL), there are no published data regarding the short-term impact of seizures on children or adults. Furthermore, utility studies in epilepsy have concentrated on examining the impact of different seizure frequencies on patients' QoL rather than the impact of seizures themselves. Given that administration of questionnaires during (or shortly after) a seizure is impossible and unethical, alternative methods are required. As part of the BUCCOLAM® (oromusocal midazolam) submission to the AWMSG, an exploratory analysis was conducted to determine the short-term impact of seizures on QoL. METHODS: Four UK clinicians were asked to qualitatively describe the impact of seizure on children and parents/ carers, to estimate utility values during and shortly after a seizure using the EQ-5D-5L questionnaire, and to assess how long it takes children to recover from seizures of different severities. RESULTS: Clinicians described the utility of patients during seizure as equivalent to death (not capable of experiencing or doing anything), and the parents'/carers' quality of life being significantly reduced (lowest level on anxiety/depression scale). Using the EQ-5D-5L, the baseline utility of a normal healthy child with epilepsy was estimated at 0.92. This decreased to -0.334 during seizure, 0.722 immediately following seizure (for a short seizure with no ambulance required) and 0.1 for a more severe seizure (where an ambulance was required). The mean prolonged acute seizure duration in children was estimated at 5-20 minutes, with time to full recovery estimated as 24 hours for a seizure not leading to hospital admission, and 3-5 days for a seizure requiring hospitalisation. CONCLUSIONS: Seizures appear to have a major impact on the QoL of both children and their parents/carers. Although short-term in nature, seizures are also associated with disproportionate recovery times, with a resulting impact on QoL.
OBJECTIVES:
The Huntington Clinical Self-Reported Instrument (H-CSRI) is the first subjective clinimetric scale for patients with Huntington's disease (HD) . Such an instrument offers the advantage of allowing a remote follow-up, and collection of information on the development of motor, functional and behavioural symptoms of HD, perceived by the patients themselves. The objective of this study was to adapt and cross-culturally validate the H-CSRI for Spain. METHODS: The original questionnaire included three subscales assessing patients' motor ability (13 Likerttype items in four dimensions), functional capacity (seven Yes/No questions) and behavioural ability (13 Likert-type items in four dimensions). The instrument was translated forwards and backwards by native speakers. The hospital 'Hospital Ramon y Cajal' provided their patients with the questionnaire. Classical test theory and item response theory were used to assess its clinimetric properties. Cross-cultural validation was assessed by differential item functioning analysis (DIF). RESULTS: A total of 59 patients filled in the H-CSRI questionnaire. The H-CSRI showed satisfactory psychometric proprieties. Item response rates ranged from 84% to 94%. A floor effect was found for five items in the behavioural dimension. The H-CSRI showed an acceptable reliability, as Cronbach's alpha coefficients were higher than 0.85. Factor analyses demonstrated that the data were structured in the same way as for the French and the Italian versions. Item internal consistency (IIC) and item discriminant validity criteria were met for most items (i.e. IIC was Ͼ 0.40, and correlations between items and their respective rest-scores in one dimension were all greater than correlations with another dimension). The DIF analyses showed no item bias versus the Italian or French versions. CONCLUSIONS: The Spanish version of the H-CSRI showed acceptable clinimetric properties. This study supports the usefulness of the H-CSRI questionnaire to assess the clinical status of patients, although it is limited by the small sample size.
PND53 PATIENT REPORTED SLEEP PROBLEMS IN THE UK
Wade A, Crawford G, Pumford N Patients Direct, Glasgow, UK OBJECTIVES: To assess the frequency, severity, use of hypnotics and impact of sleep problems in the community in the UK. METHODS: Questionnaires were inserted in a national newspaper and patients with sleep problems requested to complete them and return by post. RESULTS: Two thousand and eighty-two questionnaires were returned. Within the questionnaires returned not all of the questions were answered with some questions being more frequently completed than others. We report the outcome for individually completed questions. Sixty-four percent of respondents were female, 92% aged forty or over and 57% over 60; 94% of patients reported insomnia for more than a year. Seventy-seven percent described sleep as bad or very bad. 64% complained of feeling tired after rising and starting the next day. Only 3% thought they got off to sleep in less than 20 minutes with 55% reporting taking greater than 1 hour to get to sleep. A total of 86% visited the doctor less than 4 times per year but apparently did not complain of insomnia; 44% reported having received hypnotics from the doctor in the past but only 2% currently taking them. Seven percent of patients attributed their sleep problems to pain; 42% of patients get up regularly to use the bathroom but in general did not attribute their sleep problems to this reason. In contrast 40% of respondents felt that their problems were purely age-related. CONCLUSIONS: Insomnia is a common, longstanding, serious problem which afflicts and impacts upon older rather than younger people. While most respondents had received hypnotics in the past they were not currently taking them despite continuing to suffer from insomnia. There appears a common acceptance that sleep problems are simply a function of ageing. This study demonstrates the need for patient education and for physicians to address the problem of insomnia in older age.
PND54 FATIGUE AND QUALITY-OF-LIFE IN MULTIPLE SCLEROSIS PATIENTS WITH SPASTICITY IN GERMANY -RESULTS OF THE MOVE 1 STUDY
Pfiffner C 1 , Henze T 2 , Zettl U 3 , Essner U 4 , Flachenecker P 5 1 IMS Health GmbH & Co. OHG, Munich, Germany, 2 Centre for Rehabilitation, Nittenau, Germany, 3 University Hospital, Rostock, Germany, 4 Almirall Hermal GmbH, Reinbek, Germany, 5 Neurological Centre for Rehabilitation -Quellenhof, Bad Wildbad, Germany OBJECTIVES: Spasticity and fatigue are common in patients with Multiple Sclerosis (MS) and can highly affect patients' quality-of-life (QoL). A burden-of-disease study was performed to gain real-life data on MS-related fatigue and the patients' and physicians' evaluation of fatigue and QoL. METHODS: The MOVE 1 (MObility Im-proVEment) study included a cross-sectional investigation of fatigue and QoL of MS spasticity patients, using the "Würzburger Erschöpfungsinventar bei Multipler Sklerose" (WEIMuS, German MS-related fatigue questionnaire) and the EQ-5D QoL instrument. WEIMuS total score (0-68; cut-off Ն32), cognitive (0 -36; cut-off Ն17) and physical (0 -32; cut-off Ն16) fatigue subscores are obtained. EQ-5D includes 5 domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with 3 answer levels (no, some and extreme problems). RESULTS: In total, 419 MS patients with spasticity were enrolled at 42 German centres from 4/2011 to 9/2011. 414 patients fulfilled selection criteria and were analyzed. Mean age was 48.6 (Ϯ 9.6) y., 64.3% were female. According to physicians, 27.3% of patients had mild, 44.0% moderate and 28.7% severe spasticity. Fatigue was recorded by physicians in 49.4% and by patients in 50.0% of cases as one of the most disturbing spasticity associated symptoms. According to WEIMuS, total fatigue cut-off score was reached by 48.0%, 53.8% and 54.5% of patients with mild, moderate or severe spasticity; while physical fatigue was observed in 52.9%, 69.6% and 66.3% and cognitive fatigue in 37.3%, 35.7% and 37.6% of these subgroups, respectively. With increasing spasticity severity the mean EQ-5D index value decreased (0.6Ϯ0.2 to 0.3Ϯ0.3) and the number of patients with "extreme problems" raised, particularly in the domains "mobility" (0% to 13.6%), "self-care" (1.0% to 20.0%) and "usual activity" (2.9% to 25.5%). CONCLUSIONS: The occurrence of fatigue in MS patients increases with spasticity severity, impairing patients' QoL in parallel. Patients' and physicians' evaluations are aligned.
PND55 MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29): ITS VALIDITY AND RESPONSIVENESS IN CLINICAL TRIAL-BASED SUBJECTS
Guo S 1 , Proskorovsky I 2 , Phillips GA 3 1 United BioSource Corporation, Lexington, MA, USA, 2 United BioSource Corporation, Dorval, QC, Canada, 3 Biogen Idec Inc., Weston, MA, USA OBJECTIVES: The psychometric properties of the Multiple Sclerosis Impact Scale (MSIS-29) have been well examined in community-based samples using crosssectional data, but not yet in trial-based samples using longitudinal data. This analysis examined MSIS-29's validity and responsiveness using longitudinal data from patients with relapsing-remitting multiple sclerosis (RRMS) enrolled in the SELECT trial of daclizumab HYP. METHODS: The MSIS-29 and EQ-5D tariff and visual analogue scale (VAS) were administered at baseline, 3, 6, and 12 months to 600 patients with RRMS who had mean age of 35.8 (SDϭ8.91) years and Expanded Disability Status Scale of 2.7 (SDϭ1.17) at baseline. The convergent and discriminant validity of MSIS-29 was assessed by examining the strength of correlations between the physical and psychological scores of the MSIS-29 and each of the five EQ-5D dimensions at all time points. MSIS-29 responsiveness was evaluated by examining the direction, magnitude, and pattern of change in MSIS-29 scores in three patient subgroups defined by achieving an established minimal important EQ-5D VAS change of 5.5 points at each time point from baseline (improved Ն5.5, -5.5 Ͻ stable Ͻ5.5, worsened Յ-5.5). RESULTS: As expected, the MSIS-29 physical scale was more highly correlated with the EQ-5D dimensions usual activities (rϭ0.66) and mobility (rϭ0.62) and least correlated with anxiety/depression (rϭ0.48). Conversely, the psychological scale was more highly correlated with the EQ-5D anxiety/depression (rϭ0.64) and least correlated with personal care (rϭ0.35) and mobility (rϭ0.42). The direction, magnitude, and pattern of change in the physical and psychological scores over time in each subgroup were consistent with expectations, showing insignificant change among stable patients, but significant change among those who improved or worsened. CONCLUSIONS: The MSIS-29 is a valid and responsive measure among trial-based subjects. This analysis supports its use as a disease-specific measure of treatment effect on the physical and psychological well-being of MS patients.
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